BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26896816)

  • 1. Statins: An undesirable class of aquatic contaminants?
    Santos MM; Ruivo R; Lopes-Marques M; Torres T; de los Santos CB; Castro LF; Neuparth T
    Aquat Toxicol; 2016 May; 174():1-9. PubMed ID: 26896816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural mechanism for statin inhibition of HMG-CoA reductase.
    Istvan ES; Deisenhofer J
    Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Istvan ES
    Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking.
    Karthik MV; Satya Deepak MV; Shukla P
    Comput Biol Med; 2012 Feb; 42(2):156-63. PubMed ID: 22177940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies.
    Dinesh N; Pallerla DS; Kaur PK; Kishore Babu N; Singh S
    Microb Pathog; 2014 Jan; 66():14-23. PubMed ID: 24239940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
    Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
    J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant 3-Hydroxy 3-Methyl Glutaryl-CoA Reductase from Candida glabrata (Rec-CgHMGR) Obtained by Heterologous Expression, as a Novel Therapeutic Target Model for Testing Synthetic Drugs.
    Andrade-Pavón D; Cuevas-Hernández RI; Trujillo-Ferrara JG; Hernández-Rodríguez C; Ibarra JA; Villa-Tanaca L
    Appl Biochem Biotechnol; 2017 Aug; 182(4):1478-1490. PubMed ID: 28138930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) enzyme.
    Leopoldini M; Malaj N; Toscano M; Sindona G; Russo N
    J Agric Food Chem; 2010 Oct; 58(19):10768-73. PubMed ID: 20843083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking.
    Islam B; Sharma C; Adem A; Aburawi E; Ojha S
    Drug Des Devel Ther; 2015; 9():4943-51. PubMed ID: 26357462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structure of the catalytic portion of human HMG-CoA reductase.
    Istvan ES; Deisenhofer J
    Biochim Biophys Acta; 2000 Dec; 1529(1-3):9-18. PubMed ID: 11111074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis.
    Istvan ES; Palnitkar M; Buchanan SK; Deisenhofer J
    EMBO J; 2000 Mar; 19(5):819-30. PubMed ID: 10698924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations.
    da Costa RF; Freire VN; Bezerra EM; Cavada BS; Caetano EW; de Lima Filho JL; Albuquerque EL
    Phys Chem Chem Phys; 2012 Jan; 14(4):1389-98. PubMed ID: 22159045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 3-hydroxy-3-methylglutaryl coenzyme-A reductases from fungi: a proposal as a therapeutic target and as a study model.
    Andrade-Pavón D; Sánchez-Sandoval E; Rosales-Acosta B; Ibarra JA; Tamariz J; Hernández-Rodríguez C; Villa-Tanaca L
    Rev Iberoam Micol; 2014; 31(1):81-5. PubMed ID: 24270073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IAF, QGF, and QDF Peptides Exhibit Cholesterol-Lowering Activity through a Statin-like HMG-CoA Reductase Regulation Mechanism: In Silico and In Vitro Approach.
    Silva M; Philadelpho B; Santos J; Souza V; Souza C; Santiago V; Silva J; Souza C; Azeredo F; Castilho M; Cilli E; Ferreira E
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of archaeal HMG-CoA reductase: insights into structural changes of the C-terminal helix of the class-I enzyme.
    Vögeli B; Shima S; Erb TJ; Wagner T
    FEBS Lett; 2019 Mar; 593(5):543-553. PubMed ID: 30702149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding thermodynamics of statins to HMG-CoA reductase.
    Carbonell T; Freire E
    Biochemistry; 2005 Sep; 44(35):11741-8. PubMed ID: 16128575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae.
    Feng L; Zhou L; Sun Y; Gui J; Wang X; Wu P; Wan J; Ren Y; Qiu S; Wei X; Li J
    Bioorg Med Chem; 2011 Jun; 19(11):3512-9. PubMed ID: 21550257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of an HMG-CoA reductase from Listeria monocytogenes that exhibits dual coenzyme specificity.
    Theivagt AE; Amanti EN; Beresford NJ; Tabernero L; Friesen JA
    Biochemistry; 2006 Dec; 45(48):14397-406. PubMed ID: 17128979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
    Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
    J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.